Last week Coupons.com (COUP), the year's third tech IPO (after Varonis (VRNS) and Care.com (CRCM)), continued a strong run for the sector with an 88% first-day gain; the three offerings now average an 83% total return to date. Others hope to cash in on...read more
Recro Pharma, a clinical-stage biotech developing non-opioid therapeutics for the treatment of pain, raised $30 million by offering 3.8 million shares at $8, below the range of $10 to $12. Recro Pharma plans to list on the NASDAQ under the symbol REPH. Aegis...read more
Last week marked the end of the greatest amount of biotech activity across a two-week stretch in over a decade (14 pricings from 1/29 to 2/11). However, without any superstar performers like January’s Dicerna (DRNA; up 160%) or Ultragenyx (RARE; 110%),...read more
US IPO Recap: Coupons.com jumps 88% and Biomet files for an IPO
Last week Coupons.com (COUP), the year's third tech IPO (after Varonis (VRNS) and Care.com (CRCM)), continued a strong run for the sector with an 88% first-day gain; the three offerings now average an 83% total return to date. Others hope to cash in on...read more
Recro Pharma prices IPO at $8, below the range
Recro Pharma, a clinical-stage biotech developing non-opioid therapeutics for the treatment of pain, raised $30 million by offering 3.8 million shares at $8, below the range of $10 to $12. Recro Pharma plans to list on the NASDAQ under the symbol REPH. Aegis...read more
3 US IPOs planned for the week of Mar 3
The following IPOs are expected to price this week: Aquinox Pharmaceuticals (AQXP), a clinical-stage biotech developing novel drug candidates to treat inflammation and...read more
US IPO Recap: Wave goodbye to the biotech wave as tech prepares to take over
Last week marked the end of the greatest amount of biotech activity across a two-week stretch in over a decade (14 pricings from 1/29 to 2/11). However, without any superstar performers like January’s Dicerna (DRNA; up 160%) or Ultragenyx (RARE; 110%),...read more